JUPITER LIFE LINE HOSP L
Latest filings
- Audio link shared for Q2 and H1 FY27 analyst call · Investor Communications
- September 2026 results: H1 revenue up 52%, profit up 57% · Compliance
- Q2 FY27 growth, Pune land purchase and 2,900-bed expansion plan · Investor Communications
Snapshot
What the business is, and whether it's a good one at a fair price.
Operates a chain of multi-specialty hospitals across western and central India — Thane, Pune, Indore and the newly commissioned Dombivli — earning ₹1,499.8 crore in FY26 (+15.2% YoY). The Dombivli greenfield (500-bed capacity with 300 beds currently fitted out across 750,000 sq ft) opened in February 2026 two months ahead of schedule, and a 400-bed quaternary-care hospital is being set up on a one-lakh-sq-ft site in BKC Mumbai, with further projects in the pipeline at Pune South, Mira Road and Thane, taking the long-term bed-count target to roughly 3,000. Revenue is driven by inpatient and outpatient volumes — 10.8 lakh volumes in FY26, with Average Revenue Per Occupied Bed at ₹67,700 and Average Length of Stay of 3.87 days; insurance payers contributed 55.4% of FY26 revenue and government schemes 1%. The model is asset-heavy and expansion-driven: FY26 capex was deployed across Dombivli, BKC land, Pune and Mira Road, with gross debt at ~₹500 crore against cash of ~₹545 crore, leaving the balance sheet net cash positive. Other operating expenses (40.9% of revenue) and employee costs (17.1%) are the largest cost lines, followed by depreciation at 5.8%. A subsidiary has separately acquired Sulcus Private Limited to set up an IV fluids and pharmaceutical manufacturing facility near Ujjain with ₹35–40 crore of further investment planned.
Scorecard
Measured from the filed financials, judged against its Hospital peers · as of FY26 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
JLHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from JUPITER LIFE LINE HOSP L's filed financials and exchange disclosures
What does JUPITER LIFE LINE HOSP L do?
JUPITER LIFE LINE HOSP L is a Healthcare Services company listed on NSE and BSE, trading under the symbol JLHL.
Is JUPITER LIFE LINE HOSP L profitable?
Yes. Over the trailing twelve months JUPITER LIFE LINE HOSP L reported a net profit of ₹186 Cr on revenue of ₹1,558 Cr.
Does JUPITER LIFE LINE HOSP L pay a dividend?
Yes. The dividend yield is 0.39% at the current price. It paid out 3% of its profit as dividend in FY26.
Is JUPITER LIFE LINE HOSP L debt-free?
No. It reported borrowings of ₹509 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹454 Cr after cash. Debt stands at 0.33× equity. That is higher than 74% of its 24 Hospital peers.
Is JUPITER LIFE LINE HOSP L expensive compared with its peers?
On trailing P/E, JUPITER LIFE LINE HOSP L ranks 4 of 30 in Hospital — cheaper than 90% of them, against an industry median of 42.2×. This is a position, not a valuation judgement.
How much does the JUPITER LIFE LINE HOSP L share price move in a day?
On a typical session JUPITER LIFE LINE HOSP L moves 0.88% — that is the median absolute close-to-close move across its last 68 trading days. MarketPing measures each filing's price reaction against it.
Where can I track JUPITER LIFE LINE HOSP L's announcements?
Every NSE and BSE filing by JUPITER LIFE LINE HOSP L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.